New immunotherapy combo aims to improve First-Line lung cancer treatment
NCT ID NCT07662395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called SCTB41, when combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced non-small cell lung cancer that has no targetable genetic mutations. The trial has two parts: an initial safety check in about 30–60 people, followed by a larger phase where 350 participants are randomly assigned to one of the two treatment combinations. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SCTB41
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with advanced non-small cell lung cancer who have no targetable genetic mutations.
- What could go wrong
- This is an early-to-mid-stage trial, so the experimental drug may not prove more effective or safer than the existing standard. Side effects from combining immunotherapy with chemotherapy can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE BLIND are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China